David Habiger Acquires 2,250 Shares of Boston Scientific (NYSE:BSX) Stock

Boston Scientific Corporation (NYSE:BSX) Director David Habiger purchased 2,250 shares of Boston Scientific stock in a transaction on Wednesday, May 20th. The stock was bought at an average cost of $55.92 per share, with a total value of $125,820.00. Following the completion of the acquisition, the director owned 13,878 shares in the company, valued at approximately $776,057.76. This trade represents a 19.35% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link.

Boston Scientific Stock Performance

NYSE:BSX opened at $57.71 on Friday. The firm’s 50-day moving average is $61.97 and its 200-day moving average is $80.25. The company has a market cap of $85.77 billion, a price-to-earnings ratio of 24.15, a PEG ratio of 1.05 and a beta of 0.62. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. Boston Scientific Corporation has a 52-week low of $52.52 and a 52-week high of $109.50.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The business had revenue of $5.20 billion for the quarter, compared to the consensus estimate of $5.19 billion. During the same period last year, the business earned $0.75 earnings per share. The firm’s revenue for the quarter was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Equities research analysts anticipate that Boston Scientific Corporation will post 3.38 earnings per share for the current year.

Boston Scientific announced that its Board of Directors has authorized a stock buyback program on Monday, May 18th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s management believes its shares are undervalued.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Several Boston Scientific directors bought shares this week, including Cheryl Pegus, David C. Habiger, and Edward J. Ludwig. Heavy insider buying often signals management confidence and can help support sentiment around BSX. Article Title
• Positive Sentiment: Boston Scientific’s board authorized a $5 billion share repurchase program, which can be viewed as a sign that management believes the stock may be undervalued and could provide downside support. Article Title
• Positive Sentiment: Boston Scientific recently reported earnings and revenue that slightly beat expectations and raised guidance for 2026, reinforcing the company’s longer-term growth story even though the stock has remained weak.
• Neutral Sentiment: Recent analyst commentary has been mixed: firms like Baird and Stifel still have positive ratings, but several price targets were trimmed, suggesting Wall Street remains constructive while tempering expectations. Article Title
• Negative Sentiment: Coverage asking why BSX is down 13% since its last earnings report highlights lingering investor concern that the stock has not kept pace with its fundamentals, likely weighing on near-term trading. Article Title

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of BSX. Murphy & Mullick Capital Management Corp raised its position in shares of Boston Scientific by 200.0% during the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 170 shares during the last quarter. FWL Investment Management LLC bought a new position in Boston Scientific in the second quarter valued at about $26,000. Swiss RE Ltd. acquired a new stake in Boston Scientific in the fourth quarter worth about $26,000. Garton & Associates Financial Advisors LLC acquired a new stake in Boston Scientific in the fourth quarter worth about $26,000. Finally, United Community Bank raised its holdings in Boston Scientific by 115.7% during the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 147 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts recently commented on the company. National Bank Financial set a $115.00 target price on Boston Scientific in a research report on Monday, February 2nd. Robert W. Baird dropped their price objective on shares of Boston Scientific from $78.00 to $75.00 and set an “outperform” rating for the company in a research note on Tuesday. Argus raised shares of Boston Scientific to a “strong-buy” rating in a report on Thursday, February 26th. Wells Fargo & Company lowered their target price on shares of Boston Scientific from $94.00 to $75.00 and set an “overweight” rating on the stock in a research note on Thursday, April 23rd. Finally, Citigroup dropped their price target on shares of Boston Scientific from $94.00 to $87.00 and set a “buy” rating for the company in a research report on Tuesday, April 7th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $92.71.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.